AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19696435 — intervention group
Group type: EXPERIMENTAL
Intervention: FFW-L/NBLI and NBLI/FFW-L (combined intervention groups)
Number of subjects: 23
Study 19696435 — intervention group
Group type: COMPARATOR
Intervention: wait/NBLI (control group)
Number of subjects: 23
Study 18508832 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30
Study 18508832 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 30
Study 16141467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (1,000 microg administered intravenously or orally daily for 3 weeks)
Number of subjects: 20
Study 16141467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 20
Study 12463577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study 12463577 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 0
Study 10102147 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (14.2 mg elemental zinc for first 417 patients and 40 mg for remaining 273 patients) for 15 days
Number of subjects: 684
Study 10102147 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (4500 microg retinol equivalent) for 15 days
Number of subjects: 684
Study 10102147 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixtures for 15 days
Number of subjects: 684
Study 7778342 — intervention group
Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 24
Study 7778342 — intervention group
Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 24
Study 2185023 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbochromen (0.125 mg kg‐1 min‐1 for 40 min i.v.)
Number of subjects: 18
Study 2185023 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (0.05 mg kg‐1 min‐1 for 10 min i.v.)
Number of subjects: 18
Study 399859 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous salbutamol tablets
Number of subjects: 22
Study 399859 — intervention group
Group type: COMPARATOR
Intervention: Intermittent salbutamol tablets
Number of subjects: 22
Study 31299447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placebo nasal spray with expectancy-modifying instructions (Protection: the spray protects from experiencing negative emotions)
Number of subjects: 128
Study 31299447 — intervention group
Group type: COMPARATOR
Intervention: Control group (Sensitization: the spray sensitizes to negative emotions)
Number of subjects: 128
Study 31299447 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo: the spray is a placebo)
Number of subjects: 128
Study 31299447 — intervention group
Group type: COMPARATOR
Intervention: Control group (Control: no nasal spray)
Number of subjects: 128
Study 28547075 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 59
Study 28547075 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve (SSN)‐pulsed radiofrequency (RF) therapy
Number of subjects: 59
Study 28547075 — intervention group
Group type: COMPARATOR
Intervention: Both PBMT and SSN-pulsed RF therapy
Number of subjects: 59
Study 26079499 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard haemostasis + TachoSil (Group 2)
Number of subjects: 70
Study 26079499 — intervention group
Group type: COMPARATOR
Intervention: Standard haemostasis (Group 1)
Number of subjects: 70
Study 23547275 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals educational program
Number of subjects: 830
Study 21599941 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific physiotherapy treatment (10 sessions over 10 weeks)
Number of subjects: 250
Study 21599941 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy advice (2 sessions over 10 weeks)
Number of subjects: 250
Study 21599941 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific physiotherapy treatment
Number of subjects: 250
Study 21599941 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy advice
Number of subjects: 250
Study 19538918 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 182
Study 19538918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study 16787125 — intervention group
Group type: COMPARATOR
Intervention: Video education/control
Number of subjects: 253
Study 16787125 — intervention group
Group type: COMPARATOR
Intervention: Brief telephone calls with no counseling
Number of subjects: 253
Study 16787125 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls with counseling
Number of subjects: 253
Study 12817519 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 2.5 to 80 mg/kg
Number of subjects: 0
Study 12817519 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL670 40- and 80-mg/kg dose levels
Number of subjects: 0
Study 11111817 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporal rheopheresis
Number of subjects: 33
Study 11111817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 8656257 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF for three consecutive courses on months 1 to 3 (CMFx3)
Number of subjects: 1554
Study 8656257 — intervention group
Group type: COMPARATOR
Intervention: CMF for 6 consecutive courses on months 1 to 6 (CMF x 6)
Number of subjects: 1554
Study 8656257 — intervention group
Group type: COMPARATOR
Intervention: CMFx3 plus three single courses of reintroduction CMF given on months 6, 9, and 12
Number of subjects: 1554
Study 8656257 — intervention group
Group type: COMPARATOR
Intervention: CMFx6 plus three single courses of reintroduction CMF given on months 9, 12, and 15
Number of subjects: 1554
Study 8656257 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction chemotherapy
Number of subjects: 1554
Study 8656257 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction chemotherapy for women aged > or = 40 years
Number of subjects: 1554
Study 8656257 — intervention group
Group type: COMPARATOR
Intervention: CMFx3 for women aged less than 40 years
Number of subjects: 1554
Study 8656257 — intervention group
Group type: COMPARATOR
Intervention: CMFx3 for patients with ER-negative tumors
Number of subjects: 1554
Study 2069512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 91
Study 2069512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 6340601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 1.5 g daily
Number of subjects: 30
Study 6340601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g daily
Number of subjects: 30
Study 6340601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 30
Study 31238907 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral treatment (9 sessions)
Number of subjects: 200
Study 31238907 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 200
Study 28121935 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline therapy at 0.6 g/d for 1 year
Number of subjects: 30
Study 28121935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no central nervous system drugs except sleeping pills and antidepressants)
Number of subjects: 30
Study 25731140 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling training of nurses (motivational interviewing and stages of change model)
Number of subjects: 188
Study 25731140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling training)
Number of subjects: 188
Study 22692126 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational music
Number of subjects: 10
Study 22692126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm beats derived from the same songs
Number of subjects: 10
Study 22692126 — intervention group
Group type: COMPARATOR
Intervention: Recovery without music
Number of subjects: 10
Study 21599615 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear frequency compression (NLFC)
Number of subjects: 15
Study 19663098 — intervention group
Group type: EXPERIMENTAL
Intervention: SPFDP plus ARCAU
Number of subjects: 124
Study 19663098 — intervention group
Group type: COMPARATOR
Intervention: ARCAU
Number of subjects: 124
Study 16685052 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 240 mL with felodipine 10 mg
Number of subjects: 18
Study 16685052 — intervention group
Group type: COMPARATOR
Intervention: Orange juice 240 mL with felodipine 10 mg
Number of subjects: 18
Study 16685052 — intervention group
Group type: COMPARATOR
Intervention: Furanocoumarin-free grapefruit juice 240 mL with felodipine 10 mg
Number of subjects: 18
Study 15474877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (2000 to 2400 mg/d) with restriction of total fluids to 1.5 L/d
Number of subjects: 65
Study 15474877 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical treatment and general nutritional recommendations
Number of subjects: 65
Study 11755608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 10 days
Number of subjects: 93
Study 11755608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 9892527 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fibre (PMX-F) treatment
Number of subjects: 24
Study 8175223 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay of peak velocity measurement
Number of subjects: 32
Study 8175223 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity of flow propagation measurement
Number of subjects: 32
Study 8175223 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between methods
Number of subjects: 32
Study 2738584 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous hepatitis B vaccine
Number of subjects: 78
Study 2738584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine
Number of subjects: 78
Study 2738584 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HIV positive adults
Number of subjects: 78
Study 30384780 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-mediated exercises
Number of subjects: 14
Study 30913978 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalled microaggression
Number of subjects: 508
Study 30913978 — intervention group
Group type: COMPARATOR
Intervention: Control event
Number of subjects: 508
Study 29061295 — intervention group
Group type: EXPERIMENTAL
Intervention: eBEACOPP (8×eBEACOPP)
Number of subjects: 434
Study 29061295 — intervention group
Group type: EXPERIMENTAL
Intervention: R-eBEACOPP (8×R-eBEACOPP)
Number of subjects: 434
Study 29061295 — intervention group
Group type: COMPARATOR
Intervention: eBEACOPP (6×eBEACOPP)
Number of subjects: 434
Study 29061295 — intervention group
Group type: EXPERIMENTAL
Intervention: 4×eBEACOPP
Number of subjects: 434
Study 29061295 — intervention group
Group type: COMPARATOR
Intervention: 8×eBEACOPP
Number of subjects: 434
Study 26164414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback group (NFG)
Number of subjects: 27
Study 26164414 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WLG)
Number of subjects: 27
Study 23221624 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of targeted training (3 times a week)
Number of subjects: 55
Study 23221624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study 21364482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein solution (CHO + P) providing 0.49 and 0.16 g·kg(‐1)·h(‐1)
Number of subjects: 8
Study 21364482 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate solution (CHO) providing 0.49 g·kg(‐1)·h(‐1)
Number of subjects: 8
Study 21364482 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate solution (CHO)
Number of subjects: 8
Study 21364482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein solution (CHO + P)
Number of subjects: 8
Study 18634158 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day prasterone for 6 months
Number of subjects: 155
Study 18634158 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 155
Study 18634158 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day prasterone for 18 months
Number of subjects: 155
Study 18634158 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day prasterone for 18 months
Number of subjects: 155
Study 16926664 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention programme (regular physical activity, low fat diet, smoking cessation)
Number of subjects: 197
Study 16926664 — intervention group
Group type: COMPARATOR
Intervention: Usual care with routine follow-up
Number of subjects: 197
Study 16926664 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance
Number of subjects: 197
Study 16926664 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status (smokers vs non-smokers)
Number of subjects: 197
Study 11935108 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-rehabilitation intervention
Number of subjects: 104
Study 11935108 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational intervention
Number of subjects: 104
Study 11935108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sherbrooke model (combination of clinical-rehabilitation and occupational interventions)
Number of subjects: 104
Study 11935108 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 104
Study 10412300 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic palliative chemotherapy with 5-fluorouracil and leucovorin
Number of subjects: 0
Study 7549760 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained health workers (HWs) conducting oral visual inspections
Number of subjects: 17812
Study 7549760 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained health workers (HWs)
Number of subjects: 17812
Study 7549760 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained HWs)
Number of subjects: 17812
Study 2247650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated TBI regimens (12 to 15 Gy)
Number of subjects: 0
Study 2247650 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Gy fractionated scheme (6 X 2 Gy)
Number of subjects: 0
Study 2247650 — intervention group
Group type: COMPARATOR
Intervention: Standard 10 Gy single dose TBI
Number of subjects: 0
Study 7470371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 500 μg
Number of subjects: 12
Study 7470371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 750 μg
Number of subjects: 12
Study 7470371 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of nicotine doses from 12.5 to 800 μg
Number of subjects: 12
Study 6403254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of cis‐platinum 40 mg/m2 IV on day 1, adriamycin 40 mg/m2 IV on day 1, and hexamethylmelamine 150 mg/m2 PO on days 2‐10 up to a maximum of 200 mg on a 4‐weekly cycle.
Number of subjects: 53
Study 6403254 — intervention group
Group type: COMPARATOR
Intervention: Moderate‐dose cyclophosphamide alone 40 mg/kg given IV intermittently every 3 weeks.
Number of subjects: 53
Study 30632428 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia
Number of subjects: 98
Study 30632428 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anesthesia
Number of subjects: 98
Study 30420965 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle reinforcement training (RESISTANCE)
Number of subjects: 72
Study 30420965 — intervention group
Group type: COMPARATOR
Intervention: Postural training (POSTURAL)
Number of subjects: 72
Study 28065179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (1.5 g/d n-3 LCPUFA)
Number of subjects: 103
Study 28065179 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 103
Study 28065179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 103
Study 24519847 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal treatment
Number of subjects: 0
Study 24519847 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 0
Study 21664779 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 57
Study 21664779 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NAE)
Number of subjects: 57
Study 21664779 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric shrinkage (CS)
Number of subjects: 57
Study 21664779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic shrinkage (DS)
Number of subjects: 57
Study 21664779 — intervention group
Group type: COMPARATOR
Intervention: Comparison of shrinkage patterns
Number of subjects: 57
Study 20051135 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg once‐daily in the evening
Number of subjects: 1233
Study 20051135 — intervention group
Group type: COMPARATOR
Intervention: MF‐DPI 200 microg twice‐daily
Number of subjects: 1233
Study 20051135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports for MF‐DPI 400 microg once‐daily
Number of subjects: 1233
Study 20051135 — intervention group
Group type: COMPARATOR
Intervention: Self-reports for MF‐DPI 200 microg twice‐daily
Number of subjects: 1233
Study 17118597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h)
Number of subjects: 150
Study 17118597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h) plus Hydroxyzine (25 mg/12 h)
Number of subjects: 150
Study 17118597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 150
Study 16244511 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized psychomotor fitness program (aerobic exercise and weight training)
Number of subjects: 199
Study 16244511 — intervention group
Group type: COMPARATOR
Intervention: General program of psychomotor therapy (different forms of physical exercises and relaxation training)
Number of subjects: 199
Study 11838838 — intervention group
Group type: EXPERIMENTAL
Intervention: keliximab 40 mg twice weekly (bw)
Number of subjects: 322
Study 11838838 — intervention group
Group type: EXPERIMENTAL
Intervention: keliximab 80 mg bw
Number of subjects: 322
Study 11838838 — intervention group
Group type: EXPERIMENTAL
Intervention: keliximab 140 mg bw
Number of subjects: 322
Study 11838838 — intervention group
Group type: EXPERIMENTAL
Intervention: keliximab 240 mg once weekly (ow)
Number of subjects: 322
Study 11838838 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 322
Study 11838838 — intervention group
Group type: EXPERIMENTAL
Intervention: keliximab 120 mg bw
Number of subjects: 322
Study 10401918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day
Number of subjects: 299
Study 7573902 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (without renal dysfunction)
Number of subjects: 30
Study 7573902 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (with renal dysfunction)
Number of subjects: 30
Study 2405733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine (300 mg)
Number of subjects: 40
Study 2405733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6107674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 878
Study 6107674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study 31427637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up and medical titration by telephone to reach set intervention targets
Number of subjects: 0
Study 31427637 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30390884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 141
Study 30390884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction
Number of subjects: 141
Study 30390884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurveda advice
Number of subjects: 141
Study 30390884 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of night shade vegetables
Number of subjects: 141
Study 30390884 — intervention group
Group type: COMPARATOR
Intervention: Standard diet of RA patients
Number of subjects: 141
Study 26295379 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for chronic pain; details on dosage and duration not specified.
Number of subjects: 0
Study 26295379 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite PROMIS symptom score; internal reliability (Cronbach's alpha=0.86) and construct validity confirmed.
Number of subjects: 0
Study 24510678 — intervention group
Group type: EXPERIMENTAL
Intervention: H2/H2 carriers (n = 5)
Number of subjects: 29
Study 24510678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (specific receptor antagonist for P2Y12)
Number of subjects: 29
Study 24510678 — intervention group
Group type: COMPARATOR
Intervention: VerifyNow assay
Number of subjects: 29
Study 22691871 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling through 'The Healthy Skin Clinic' intervention program
Number of subjects: 300
Study 22691871 — intervention group
Group type: COMPARATOR
Intervention: Conventional information (control group)
Number of subjects: 300
Study 20164485 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Newborn Care training
Number of subjects: 119009
Study 20164485 — intervention group
Group type: COMPARATOR
Intervention: Neonatal Resuscitation Program training
Number of subjects: 119009
Study 17922978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily in the evening
Number of subjects: 0
Study 17922978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 400 microg twice daily (BID)
Number of subjects: 0
Study 17922978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200-400 microg once daily
Number of subjects: 0
Study 17922978 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15695959 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapies and shoulder arthrography with intra-articular steroid
Number of subjects: 0
Study 15695959 — intervention group
Group type: COMPARATOR
Intervention: Physical therapies alone
Number of subjects: 0